{
  "authors": [
    {
      "author": "Athanasios Anastasiadis"
    },
    {
      "author": "Dimitrios Margaritis"
    },
    {
      "author": "Ioannis Kotsianidis"
    },
    {
      "author": "Emmanouil Spanoudakis"
    },
    {
      "author": "Anna Christoforidou"
    },
    {
      "author": "Ioannis Kostopoulos"
    },
    {
      "author": "Constantinos Tsatalas"
    }
  ],
  "doi": "10.4076/1757-1626-2-6913",
  "publication_date": "2009-11-18",
  "id": "EN118172",
  "url": "https://pubmed.ncbi.nlm.nih.gov/19918496",
  "source": "Cases journal",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "8 weekly courses of rituximab were administered to a patient who presented with pure red cell aplasia secondary to newly diagnosed splenic marginal zone lymphoma. Transfusion independence was achieved after the 6(th) course, and pure red cell aplasia receded completely with therapy."
}